ProQR Therapeutics NV (PRQR)
3.62
+0.01
(+0.28%)
USD |
NASDAQ |
Nov 22, 16:00
3.63
+0.01
(+0.28%)
After-Hours: 20:00
ProQR Therapeutics Total Liabilities (Quarterly): 91.44M for Sept. 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | 91.44M |
June 30, 2024 | 91.32M |
March 31, 2024 | 96.17M |
December 31, 2023 | 106.66M |
September 30, 2023 | 101.29M |
June 30, 2023 | 104.86M |
March 31, 2023 | 108.29M |
December 31, 2022 | 112.22M |
September 30, 2022 | 56.21M |
June 30, 2022 | 96.18M |
March 31, 2022 | 100.47M |
December 31, 2021 | 109.09M |
September 30, 2021 | 78.07M |
June 30, 2021 | 53.33M |
March 31, 2021 | 49.74M |
December 31, 2020 | 51.88M |
September 30, 2020 | 49.43M |
June 30, 2020 | 15.67M |
March 31, 2020 | 24.58M |
December 31, 2019 | 26.55M |
September 30, 2019 | 23.68M |
June 30, 2019 | 22.76M |
Date | Value |
---|---|
March 31, 2019 | 23.37M |
December 31, 2018 | 20.07M |
September 30, 2018 | 19.28M |
June 30, 2018 | 17.12M |
March 31, 2018 | 15.80M |
December 31, 2017 | 16.53M |
September 30, 2017 | 15.14M |
June 30, 2017 | 13.27M |
March 31, 2017 | 13.24M |
December 31, 2016 | 13.12M |
September 30, 2016 | 12.77M |
June 30, 2016 | 14.46M |
March 31, 2016 | 12.69M |
December 31, 2015 | 11.27M |
September 30, 2015 | 10.29M |
June 30, 2015 | 10.54M |
March 31, 2015 | 8.291M |
December 31, 2014 | 7.105M |
September 30, 2014 | 6.885M |
June 30, 2014 | 6.929M |
December 31, 2013 | 6.342M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
15.67M
Minimum
Jun 2020
112.22M
Maximum
Dec 2022
76.17M
Average
91.38M
Median
Total Liabilities (Quarterly) Benchmarks
uniQure NV | 589.98M |
Merus NV | 141.42M |
argenx SE | -- |
Pharming Group | 199.72M |
Pharvaris NV | 18.30M |
Total Liabilities (Quarterly) Related Metrics
Total Assets (Quarterly) | 119.34M |
Shareholders Equity (Quarterly) | 27.90M |
Debt to Equity Ratio | 0.1805 |
Current Ratio | 2.331 |
Net Debt Paydown Yield | 0.27% |